Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12951609 | 1.00 | MMP8 (0.54) | MMP8PKMLMNAPIN1KMT2A | |
| SCHEMBL2312705 | 1.00 | MMP8 (0.54) | MMP8PKMLMNAPIN1KMT2A | |
| SCHEMBL28263659 | 0.86 | LMNA (0.51) | PKMLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16672673 | 0.85 | MMP8 (0.54) | MMP8LMNAPIN1KMT2AMEN1 | |
| SCHEMBL17653672 | 0.85 | MMP8 (0.54) | MMP8LMNAPIN1KMT2AMEN1 | |
| SCHEMBL2064207 | 0.85 | PKM (0.48) | MMP8PKMLMNAPIN1KMT2A | |
| SCHEMBL27652260 | 0.85 | MMP8 (0.54) | MMP8LMNAPIN1KMT2AMEN1 | |
| SCHEMBL13417663 | 0.84 | MMP8 (0.53) | MMP8LMNAPIN1KMT2AMEN1 | |
| SCHEMBL12987479 | 0.84 | KMT2A (0.47) | PKMLMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12987483 | 0.84 | KMT2A (0.47) | PKMLMNAKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271195-B2 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2007-09-18 | — | — | US | claimed |
| EP-1635800-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2005-02-03 | — | — | US | claimed |
| WO-2004110418-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2004-12-23 | — | — | WO | claimed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-116761848-A | Crosslinked gel formulations | 依视路国际公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116135892-A | Method for preparing bimodal polyethylene resin for pipe material and bimodal polyethylene resin thereof | 中国石油化工股份有限公司 | 2023-05-19 | — | — | CN | disclosed |
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1959967-A2 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1635800-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060030554-A1 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. | 2006-02-09 | — | — | US | disclosed |
| US-20060030543-A1 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005120515-A2 | NOVEL SULFONAMIDES AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004110418-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030543-A1 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC3, HDAC5 | MMP8 1172/4885PKM 597/4885LMNA 1450/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | MMP8 2434/4885PKM 4106/4885LMNA 2756/4885 |
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC5, HDAC1 | MMP8 3278/4885PKM 417/4885LMNA 1405/4885 |
| US-20060030554-A1 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC3, HDAC5 | MMP8 1242/4885PKM 576/4885LMNA 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.